Neoadjuvant chemoradiotherapy with 5-fluorouracil-cisplatin combined with cetuximab in patients with resectable locally advanced esophageal carcinoma: A prospective phase I/II trial (FFCD-PRODIGE 3)—Preliminary phase II results.

Laetitia Dahan,Christophe Mariette,Marc Ychou,Tan Dat Nguyen,Rosine Guimbaud,Thomas Aparicio,Véronique Vendrely,X.B. D’Journo,Fabien Subtil,Franck Bonnetain,Antoine Adenis,Jean-François Seitz

Neoadjuvant chemoradiotherapy with 5-fluorouracil-cisplatin combined with cetuximab in patients with resectable locally advanced esophageal carcinoma: A prospective phase I/II trial (FFCD-PRODIGE 3)—Preliminary phase II results.

2017

Laetitia Dahan
Christophe Mariette
Marc Ychou
Tan Dat Nguyen
Rosine Guimbaud
Thomas Aparicio
Véronique Vendrely
X.B. D’Journo
Fabien Subtil
Franck Bonnetain
Antoine Adenis
Jean-François Seitz

4091 Background: Chemoradiotherapy (CRT) for locally advanced esophageal cancer is based on 5FU combined with cisplatin. The anti-EGFR antibody cetuximab increases the efficacy of RT-based regimen ...

Keywords:

Internal medicine
Cetuximab
Carcinoma
Oncology
Regimen
Pathology
Chemoradiotherapy
Esophageal cancer
Medicine
Fluorouracil
Cisplatin
locally advanced

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations